Table 1.
Association between the definitions of remission and mucosal healing and actual healing rates in patients with ulcerative colitis treated with mesalazine
| Author | Design | Study | Timing of endoscopy | Endoscopic index | Def. of MH | No of pat. Achieving MH |
| Vecchi (2001) | Mc, RCT | Mesalazine 4 g orally vs 2 + 2 g orally and enema | 6 wk | Rachmilewitz | Rachmilewitz < 4 | 58% vs 71% |
| Malchow (2002) | Mc, db, RCT | Mesalazine 4 g enema vs 1 g foam | 4 wk | Rachmilewitz | Rachmilewitz < 2 | 38% vs 37% |
| Mansfield (2002) | Mc, db, RCT | Balsalazide 6.75 g vs sulfasal. 3g | 8 wk | 4 point scale | Score of 0 = normal mucosa | 27% vs 25% |
| Hanauer (2007) Ascend | Mc, db, RCT | Asacol 4.8 g vs 2.4 g | 6 wk | Descriptive, no score | Normal endoscopic finding | 25% vs 20% |
| Kamm (2007) MMX | Mc, db, RCT | MMX mes. 4.8 g vs 2.4 g vs placebo | 8 wk | Mod. Sutherland index | Mod Sutherland index < 1 | 77% vs 69% vs 46% |
| Kruis (2009) | Mc, db, RCT | Mesalazine 3 g vs 1g x 3 | 8 wk | Rachmilewitz | Rachmilewitz < 4 | 71% vs 70% |
Mc: Multicenter; db: Double-blind; RCT: Randomized controlled trial; MH: Mesalazine.